| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Biology, Immunology, Cytokines |
Urology Research and Gene Therapy Laboratory, Departments of Urology [G. N. T., I. K., U. E. S.] and Pathology [R. M.], University of Berne, CH-3010 Berne, Switzerland; Molecular Urology and Therapeutics, Department of Urology, University of Virginia Health Science Center, Charlottesville, Virginia 22908 [R. A. S., L. W. K. C.]; and Basic Sciences, Dental Branch, University of Texas Health Science Center, Houston, Texas 77030 [R. E. D., J. A. K., C. M. F. C.]
Human prostate cancer has the propensity to metastasize to the bone where reciprocal cellular interactions between prostate cancer and bone cells are known to occur. Osteopontin (OPN), a noncollagenous bone extracellular matrix, is a secreted adhesive glycoprotein with a functional RGD cell-binding domain that interacts with the 
vß3 cell surface integrin heterodimer. OPN has been associated with malignant transformation as well as being ligand to the CD44 receptor. Polyclonal antibodies to human OPN (hOPN) were prepared, and specificity was shown by preabsorption with recombinant hOPN. The stimulatory effect of hOPN protein and the inhibitory effect of hOPN antibody on human prostate cancer cell lines LNCaP and C4-2 were assessed by induction or inhibition of anchorage-independent growth, respectively. Expression of hOPN mRNA in prostate cancer cell lines and human prostate cancer tissue specimens were measured by mRNA blot analysis. Protein expression was assessed by immunohistochemistry in human prostate cancer specimens and by Western blot analysis in prostate cancer cell lines. hOPN stimulated anchorage-independent growth of the human prostate cancer cell lines LNCaP and C4-2 in vitro. Antibodies to hOPN inhibited the growth-stimulatory effect by endogenous OPN, which can be overcome by the addition of exogenous hOPN. hOPN mRNA and protein are expressed in human prostate cancer cell lines in vitro and in clinical human prostate cancer specimens. These findings taken together suggest that OPN may act as a paracrine and autocrine mediator of prostate cancer growth and progression.
This article has been cited by other articles:
|
|
 |
|
  L. H. El Touny and P. P. Banerjee Identification of a Biphasic Role for Genistein in the Regulation of Prostate Cancer Growth and Metastasis Cancer Res., April 15, 2009; 69(8): 3695 - 3703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Desai, T. Ma, and M. A. Chellaiah Invadopodia and Matrix Degradation, a New Property of Prostate Cancer Cells during Migration and Invasion J. Biol. Chem., May 16, 2008; 283(20): 13856 - 13866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-L. Chang, L. Harkins, Y.-H. Hsieh, P. Hicks, K. Sappayatosok, S. Yodsanga, S. Swasdison, A. F. Chambers, C. A. Elmets, and K.-J. Ho Osteopontin Expression in Normal Skin and Non-melanoma Skin Tumors J. Histochem. Cytochem., January 1, 2008; 56(1): 57 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Gregoire, H. Porte, M.-C. Copin, and P. Lassalle Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment Clin. Cancer Res., May 15, 2007; 13(10): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kato, K. Kitahara, S. R Rittling, K. Nakashima, D. T Denhardt, H. Kurosawa, Y. Ezura, and M. Noda Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone J. Endocrinol., April 1, 2007; 193(1): 171 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, M. Abe, M. Hiasa, A. Oda, H. Amou, A. Nakano, K. Takeuchi, K. Kitazoe, S. Kido, D. Inoue, et al. Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin Clin. Cancer Res., February 1, 2007; 13(3): 816 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Petrik, P. W. Lavori, H. Cao, Y. Zhu, P. Wong, E. Christofferson, M. J. Kaplan, H. A. Pinto, P. Sutphin, A. C. Koong, et al. Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers J. Clin. Oncol., November 20, 2006; 24(33): 5291 - 5297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Hsieh, M. M. Juliana, P. H. Hicks, G. Feng, C. Elmets, L. Liaw, and P.-L. Chang Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res., July 15, 2006; 66(14): 7119 - 7127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Wai, Z. Mi, C. Gao, H. Guo, C. Marroquin, and P. C. Kuo Ets-1 and Runx2 Regulate Transcription of a Metastatic Gene, Osteopontin, in Murine Colorectal Cancer Cells J. Biol. Chem., July 14, 2006; 281(28): 18973 - 18982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jain, G. Chakraborty, and G. C. Kundu The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C {alpha}/c-Src/I{kappa}B Kinase {alpha}/{beta}-Dependent Prostate Tumor Progression and Angiogenesis. Cancer Res., July 1, 2006; 66(13): 6638 - 6648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., March 1, 2006; 66(5): 2815 - 2825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ito, Y. Hashimoto, E. Tanaka, T. Kan, S. Tsunoda, F. Sato, M. Higashiyama, T. Okumura, and Y. Shimada An Inducible Short-Hairpin RNA Vector against Osteopontin Reduces Metastatic Potential of Human Esophageal Squamous Cell Carcinoma In vitro and In vivo Clin. Cancer Res., February 15, 2006; 12(4): 1308 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Khodavirdi, Z. Song, S. Yang, C. Zhong, S. Wang, H. Wu, C. Pritchard, P. S. Nelson, and P. Roy-Burman Increased Expression of Osteopontin Contributes to the Progression of Prostate Cancer Cancer Res., January 15, 2006; 66(2): 883 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Donati, L. Boldrini, M. Dell'Omodarme, M. C. Prati, P. Faviana, T. Camacci, M. Lucchi, A. Mussi, M. Santoro, F. Basolo, et al. Osteopontin Expression and Prognostic Significance in Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6459 - 6465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mentor-Marcel, C. A. Lamartiniere, I. A. Eltoum, N. M. Greenberg, and A. Elgavish Dietary Genistein Improves Survival and Reduces Expression of Osteopontin in the Prostate of Transgenic Mice with Prostatic Adenocarcinoma (TRAMP) J. Nutr., May 1, 2005; 135(5): 989 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Wai, Z. Mi, H. Guo, S. Sarraf-Yazdi, C. Gao, J. Wei, C. E. Marroquin, B. Clary, and P. C. Kuo Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis Carcinogenesis, April 1, 2005; 26(4): 741 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Huang, Z. Xie, H. Konaka, J. Sodek, H. E. Zhau, and L. W.K. Chung Human Osteocalcin and Bone Sialoprotein Mediating Osteomimicry of Prostate Cancer Cells: Role of cAMP-Dependent Protein Kinase A Signaling Pathway Cancer Res., March 15, 2005; 65(6): 2303 - 2313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, N. S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R. H. Hruban, C. J. Yeo, and M. Goggins Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 487 - 491. [Abstract] [Full Text]
|
|
|
|
|
|
S. Schneider, J. Yochim, J. Brabender, K. Uchida, K. D. Danenberg, R. Metzger, P. M. Schneider, D. Salonga, A. H. Holscher, and P. V. Danenberg Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1588 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Coppola, M. Szabo, D. Boulware, P. Muraca, M. Alsarraj, A. F. Chambers, and T. J. Yeatman Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies Clin. Cancer Res., January 1, 2004; 10(1): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. De, J. Chen, N. V. Narizhneva, W. Heston, J. Brainard, E. H. Sage, and T. V. Byzova Molecular Pathway for Cancer Metastasis to Bone J. Biol. Chem., October 3, 2003; 278(40): 39044 - 39050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Freeman, R. D. Gangula, B. E. Welm, M. Ozen, B. A. Foster, J. M. Rosen, M. Ittmann, N. M. Greenberg, and D. M. Spencer Conditional Activation of Fibroblast Growth Factor Receptor (FGFR) 1, but not FGFR2, in Prostate Cancer Cells Leads to Increased Osteopontin Induction, Extracellular Signal-regulated Kinase Activation, and in Vivo Proliferation Cancer Res., October 1, 2003; 63(19): 6237 - 6243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Agrawal, T. Chen, R. Irby, J. Quackenbush, A. F. Chambers, M. Szabo, A. Cantor, D. Coppola, and T. J. Yeatman Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling J Natl Cancer Inst, April 3, 2002; 94(7): 513 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Kim, S. J. Skates, T. Uede, K.-k. Wong, J. O. Schorge, C. M. Feltmate, R. S. Berkowitz, D. W. Cramer, and S. C. Mok Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer JAMA, April 3, 2002; 287(13): 1671 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Fedarko, A. Jain, A. Karadag, M. R. Van Eman, and L. W. Fisher Elevated Serum Bone Sialoprotein and Osteopontin in Colon, Breast, Prostate, and Lung Cancer Clin. Cancer Res., December 1, 2001; 7(12): 4060 - 4066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Q. Zheng, A. S. Woodard, G. Tallini, and L. R. Languino Substrate Specificity of alpha vbeta 3 Integrin-mediated Cell Migration and Phosphatidylinositol 3-Kinase/AKT Pathway Activation J. Biol. Chem., August 4, 2000; 275(32): 24565 - 24574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Bayless and G. E. Davis Identification of Dual alpha 4beta 1 Integrin Binding Sites within a 38 Amino Acid Domain in the N-terminal Thrombin Fragment of Human Osteopontin J. Biol. Chem., April 13, 2001; 276(16): 13483 - 13489. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
